Drug
Pasireotide clinical trials
Also written SOM230.
- studies test it
- 56
- open now
- 1
- in phase 3
- 7
- first study started
- 2004
Keep track of what changes. Save the pasireotide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
56 studies that test it; most in 2011 (9)
| Year | Studies |
|---|---|
| 2004 | 5 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 6 |
| 2009 | 4 |
| 2010 | 5 |
| 2011 | 9 |
| 2012 | 6 |
| 2013 | 5 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 36
- Phase 3
- 7
- Phase 4
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 24 · Other 32
Novartis Pharmaceuticals (22) · Emory University (2) · NYU Langone Health (2) · Memorial Sloan Kettering Cancer Center (2) · Hospices Civils de Lyon (1) · Nxera Pharma UK Limited (1) · RECORDATI GROUP (1) · Anthony Sung, MD (1)
Often tested with
Tested in the same studies.
Everolimus (6) · HTL0030310 (1) · Docetaxel (1) · Prednisone (1) · Cabergoline (1) · Octreotide (1) · Topotecan (1) · Bortezomib (1)
Studies
Open first, then newest update. How each study uses pasireotide is read from its arms, and is right about nine times in ten.
Testing it · 56
- A Study of Pasireotide in People With ProlactinomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06295952Written as Pasireotide
- Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical TreatmentCompletedPhase 2Hospices Civils de LyonNCT02713776Written as Pasireotide
- A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310CompletedPhase 1Nxera Pharma UK LimitedNCT03847207Written as Pasireotide
- Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored StudiesCompletedPhase 4RECORDATI GROUPNCT01794793Written as Pasireotide
- Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal CarcinomatosisTerminatedPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT04826432Written as Pasireotide 0.9 MG/ML
- Pasireotide Treatment for Neuroendocrine TumorWithdrawnPhase 4University of Maryland, BaltimoreNCT02779257Written as Pasireotide
- Pasireotide in Prevention of GI ToxicityCompletedPhase 2Anthony Sung, MDNCT02215070Written as Pasireotide
- Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic HypoglycemiaCompletedPhase 1University of Colorado, DenverNCT03103009Written as Pasireotide
- An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With AcromegalyCompletedPhase 2Novartis PharmaceuticalsNCT00171730Written as Pasireotide
- Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's DiseaseCompletedPhase 2Novartis PharmaceuticalsNCT00171951Written as Pasireotide
- Pasireotide in Hyperinsulinemic HypoglycemiaWithdrawnPhase 2Montefiore Medical CenterNCT03053284Written as Pasireotide 0.6Mg Solution for Injection
- Pasireotide LAR Therapy of Silent Corticotroph Pituitary TumorsTerminatedPhase 2Columbia UniversityNCT02749227Written as Pasireotide LAR
- 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA TrialCompletedPhase 2Novartis PharmaceuticalsNCT01563354Written as Pasireotide LAR
- Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate CancerCompletedPhase 1/2Barbara Ann Karmanos Cancer InstituteNCT01468532Written as pasireotide
- Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid CancerCompletedPhase 2Emory UniversityNCT01270321Written as Pasireotide
- Safety and Efficacy Study of SOM230 s.c. in Cluster HeadacheTerminatedPhase 2Novartis PharmaceuticalsNCT02619617Written as SOM230
- Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid DiseaseCompletedPhase 1Novartis PharmaceuticalsNCT00446082Written as Pasireotide
- Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)CompletedPhase 1Novartis PharmaceuticalsNCT01364415Written as Pasireotide LAR
- Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate CancerCompletedPhase 1Novartis PharmaceuticalsNCT01646684Written as SOM230
- Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic FunctionCompletedPhase 1Novartis PharmaceuticalsNCT00698464Written as Pasireotide
See all 56 studies that test pasireotide →
Given in every arm · 4 — pasireotide is usual care beside what is tested
- Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate CancerTerminatedPhase 2Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNCT01313559Written as Pasireotide
- Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or AcromegalyCompletedPhase 4Novartis PharmaceuticalsNCT02060383Written as Pasireotide s.c.
- Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETsCompletedPhase 1Novartis PharmaceuticalsNCT01590199Written as SOM230
- Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's DiseaseCompletedPhase 3Novartis PharmaceuticalsNCT01374906Written as pasireotide LAR
As the comparator · 1 — what is tested is compared with pasireotide
Codes
What other systems call pasireotide · ClinicalTrials.gg INT005042
- MeSH (NLM) C517782pasireotideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 98H1T17066PASIREOTIDEConfirmed FDA, NLM, Wikidata
- RxNorm 1364105Confirmed FDA, Wikidata
- Wikidata Q3896970pasireotideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C69131PasireotideConfirmed FDA, Wikidata
- DrugBank DB06663One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C517782 | pasireotide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 98H1T17066 | PASIREOTIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1364105 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3896970 | pasireotide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C69131 | Pasireotide | Confirmed FDA, Wikidata |
| DrugBank | DB06663 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.